Bradley Pharmaceuticals Inc - Current report filing (8-K)
December 14 2007 - 8:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of
earliest event reported): December 14, 2007
BRADLEY
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
|
|
0-31680
(Commission File Number)
|
|
22-2581418
(IRS Employer
Identification No.)
|
383
Route 46 West, Fairfield, New Jersey
(Address of principal executive
offices)
|
|
|
|
07004
(Zip Code)
|
Registrants
telephone number, including area code:
(973) 882-1505
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2. below):
|_|
|
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|X|
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|_|
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|_|
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01
Other Events
On December 14, 2007, Bradley
Pharmaceuticals, Inc. (the Company) issued a press release announcing the
launch of Veregen(TM) (sinecatechins) Ointment, 15%, indicated for the topical treatment
of external genital (EGW) and perianal warts (Condylomata acuminata) in immunocompetent
patients 18 years and older. A copy of the press release is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by reference. The Company
makes no admission as to the materiality of any information in the press release.
Additional Information
About the Proposed Transaction and Where You Can Find It
In connection with the proposed
merger, the Company intends to file a proxy statement and other relevant materials with
the Securities and Exchange Commission (SEC). BEFORE MAKING ANY VOTING
DECISION WITH RESPECT TO THE PROPOSED TRANSACTION, STOCKHOLDERS OF BRADLEY
PHARMACEUTICALS ARE URGED TO READ THE PROXY STATEMENT, WHEN IT BECOMES AVAILABLE, AND THE
OTHER RELEVANT MATERIALS FILED BY THE COMPANY WITH THE SEC BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The proxy statement and other
relevant materials, when available, and any other documents filed by the Company with the
SEC, may be obtained free of charge at the SECs website at www.sec.gov. In
addition, Company stockholders may obtain free copies of the documents filed with the SEC
on the Companys website (
www.bradpharm.com
) or by contacting the Company at Bradley
Pharmaceuticals, Inc., Investor Relations at 383 Route 46 West, Fairfield, NJ 07004,
Telephone: (973) 882-1505, ext 252. You may also read and copy any reports, statements
and other information filed by the Company with the SEC at the SEC public reference room
at 100 F Street, N.E. Room 1580, Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330 or visit the SECs website for further information on its public
reference room.
The Company and its directors,
executive officers and other members of its management may be deemed to be soliciting
proxies from the Companys stockholders in favor of the Merger. Investors and
stockholders may obtain more detailed information regarding the direct and indirect
interests in the merger of persons who may, under the rules of the SEC, be considered
participants in the solicitation of the Companys stockholders in connection with
the Merger by reading the preliminary and definitive proxy statements regarding the
Merger, which will be filed with the SEC. Information about the Companys directors
and executive officers may be found in the Companys definitive proxy statement
filed with the SEC on May 17, 2007. These documents will be available free of charge once
available at the SECs web site at www.sec.gov or by directing a request to the
Company as provided above.
Item 9.01
Financial Statements and Exhibits.
99.1
|
|
Press
Release dated December 14, 2007 re launch of Veregen
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BRADLEY
PHARMACEUTICALS, INC.
|
|
By:
|
/s/ R. Brent Lenczycki
R. Brent Lenczycki, CPA
Chief Financial Officer and
Vice President
|
Dated: December 14, 2007
Bradley (NYSE:BDY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bradley (NYSE:BDY)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bradley Pharmaceuticals (New York Stock Exchange): 0 recent articles
More Bradley Pharmaceuticals Inc News Articles